United Health Products (UEEC) 10-K 28 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 27, 2023	Jun. 30, 2022
Cover [Abstract]
Entity Registrant Name	UNITED HEALTH PRODUCTS, INC.
Entity Central Index Key	0001096938
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		234,343,534
Entity Public Float			$ 95,021,555
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-27781
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	84-1517723
Entity Address Address Line 1	526 Commerce Circle
Entity Address Address Line 2	Ste. #120
Entity Address City Or Town	Mesquite
Entity Address Postal Zip Code	89027
City Area Code	475
Icfr Auditor Attestation Flag	false
Local Phone Number	755-1005
Entity Interactive Data Current	Yes
Entity Address State Or Province	NV
Auditor Name	Mac Accounting Group, LLP
Auditor Location	Midvale, Utah
Auditor Firm Id	6258

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and Cash Equivalents	$ 13,377	$ 21,799
Inventory	34,730	0
Prepaid and other current assets	22,932	5,000
Total current assets	71,039	26,799
Deferred offering costs	243,039	0
Patents, net	36,450	0
TOTAL ASSETS	350,528	26,799
Current Liabilities
Accounts payable and accrued expenses	1,255,232	826,486
Accrued liabilities - related parties	172,579	3,207
Accrued litigation settlement	300,000	120,000
Promissory note payable	9,136	0
Loans payable - related parties	4,000	219,000
Convertible notes payable, net of debt discount	196,177	0
Convertible notes payable - related party, net of debt discount	478,331	0
Total current liabilities	2,415,455	1,168,693
TOTAL LIABILITIES	2,415,455	1,168,693
Commitments and Contingencies	0	0
Stockholders' Deficit
Series A Convertible Preferred Stock - $0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding	0	0
Common Stock - $0.001 par value, 300,000,000 shares Authorized, 230,871,034 and 228,667,229 shares issued and outstanding at December 31, 2022 and December 31, 2021	230,871	228,667
Subscription Receivable	(50,550)	0
Additional Paid-In Capital	71,830,695	71,017,881
Accumulated Deficit	(74,075,943)	(72,388,442)
Total Stockholders' Deficit	(2,064,927)	(1,141,894)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 350,528	$ 26,799

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	230,871,034	228,667,229
Common stock, shares outstanding	230,871,034	228,667,229
Series A Convertible Preferred Stock [Member]
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statements of Operations
Revenues	$ 37,500	$ 59
Cost of sales	18,644	25
Gross profit	18,856	34
Operating Costs and Expenses
Selling, general and administrative expenses	2,196,331	29,563,211
Research and development expenses	624,564	237,458
Total Operating Expenses	2,820,895	29,800,669
Loss from Operations	(2,802,039)	(29,800,635)
Other income (expenses)
Interest expense	(17,022)	(226,139)
Interest expense - related party	(61,823)	(392,112)
Loss on settlement of debt	(209,598)	(434,570)
Other income	1,402,981	304,273
Total other income (expense)	1,114,538	(748,548)
Income tax expense	0	0
Net Loss	$ (1,687,501)	$ (30,549,183)
Net Loss per common share:
Basic and diluted	$ (0.01)	$ (0.14)
Weighted average number of shares outstanding	229,718,142	225,741,684

Statement of Stockholders Equit

Statement of Stockholders Equity - USD ($)	Total	Common Stock	Additional Paid-In Capital	Subscription Receivable	Accumulated Deficit
Balance, shares at Dec. 31, 2020		189,357,090
Balance, amount at Dec. 31, 2020	$ (953,262)	$ 189,357	$ 40,696,640	$ 0	$ (41,839,259)
Beneficial conversion feature	234,912	$ 0	234,912	0	0
Issuance of common stock for services and compensation, shares		34,715,000
Issuance of common stock for services and compensation, amount	26,861,097	$ 34,715	26,826,382	0	0
Sale of common stock, shares		556,455
Sale of common stock, amount	479,802	$ 557	479,245	0	0
Cancelled shares, shares		(117,647)
Cancelled shares, amount	0	$ (118)	118	0	0
Common stock issued for litigation settlement, shares		300,000
Common stock issued for litigation settlement, amount	312,000	$ 300	311,700	0	0
Common stock issued to settle accrued liabilities - related party, shares		1,013,085
Common stock issued to settle accrued liabilities - related party, amount	867,368	$ 1,013	866,355	0	0
Common stock issued to settle related party advances, shares		25,000
Common stock issued to settle related party advances, amount	26,750	$ 25	26,725	0	0
Common stock issued to settle accrued liabilities, shares		380,000
Common stock issued to settle accrued liabilities, amount	311,600	$ 380	311,220	0	0
Common stock issued for conversion of convertible notes payable and accrued interest, shares		1,085,135
Common stock issued for conversion of convertible notes payable and accrued interest, amount	590,467	$ 1,085	589,382	0	0
Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares		1,353,111
Common stock issued for conversion of convertible notes payable and accrued interest - related party, amount	676,555	$ 1,353	675,202	0	0
Net Loss	(30,549,183)	$ 0		0	(30,549,183)
Amortization of deferred offering costs	0
Balance, shares at Dec. 31, 2021		228,667,229
Balance, amount at Dec. 31, 2021	(1,141,894)	$ 228,667	71,017,881	0	(72,388,442)
Beneficial conversion feature	0
Issuance of common stock for services and compensation, shares		1,170,000
Issuance of common stock for services and compensation, amount	483,450	$ 1,170	482,280	0	0
Sale of common stock, shares		579,028
Sale of common stock, amount	149,687	$ 579	149,108	0	0
Common stock issued to settle accrued liabilities - related party, shares		425,000
Common stock issued to settle accrued liabilities - related party, amount	204,000	$ 425	203,575	0	0
Common stock issued to settle accrued liabilities, shares		672,919
Common stock issued to settle accrued liabilities, amount	254,001	$ 673	253,328	0	0
Common stock issued for conversion of convertible notes payable and accrued interest, shares		827,397
Common stock issued for conversion of convertible notes payable and accrued interest, amount	289,072	$ 827	288,245	0	0
Net Loss	(1,687,501)	$ 0	0	0	(1,687,501)
Common stock repurchased and cancelled, shares		(2,478,115)
Common stock repurchased and cancelled, amount	(858,781)	$ (2,478)	(856,303)	0	0
Common stock issued for commitment fee, shares		757,576
Common stock issued for commitment fee, amount	250,000	$ 758	249,242	0	0
Common stock issued for a stock subscription receivable, shares		250,000
Common stock issued for a stock subscription receivable, amount	0	$ 250	50,300	(50,550)	0
Amortization of deferred offering costs	(6,961)	$ 0	(6,961)	0	0
Balance, shares at Dec. 31, 2022		230,871,034
Balance, amount at Dec. 31, 2022	$ (2,064,927)	$ 230,871	$ 71,830,695	$ (50,550)	$ (74,075,943)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net Loss	$ (1,687,501)	$ (30,549,183)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Stock for services and compensation	483,450	26,861,097
Loss on settlement of debt	209,598	434,570
Write-off of inventory	0	69,649
Write-off of property and equipment	0	101,350
Stock issued for litigation settlement	0	312,000
Amortization of debt discount	16,533	608,710
Amortization expense	4,050	0
Stock received as other income	(808,781)
Changes in assets and liabilities:
Inventory	(34,730)	25
Prepaid and other current assets	(17,932)	(5,000)
Accounts payable and accrued expenses	638,721	693,692
Accrued litigation settlement	280,000	120,000
Accrued liabilities - related party	296,872	525,011
Net Cash Used In Operating Activities	(619,720)	(828,079)
Cash Flows from Investing Activities:
Purchase of patents	(40,500)
Net Cash Used In Investing Activities	(40,500)	0
Cash Flows from Financing Activities:
Repayment to on loan payable - related parties	(226,275)	(36,500)
Proceeds from loan payable - related parties	383,275	245,500
Repayments on promissory note payable	(90,864)	0
Repurchase of common stock	(50,000)
Proceeds from convertible notes payable - related party	93,000	0
Proceeds from convertible notes payable	392,975	115,000
Payment of offering costs	(26,200)
Proceeds from issuance of common stock	175,887	479,802
Net Cash Provided By Financing Activities	651,798	803,802
Increase (decrease) in Cash and Cash Equivalents	(8,422)	(24,277)
Cash and Cash Equivalents - Beginning of period	21,799	46,076
CASH AND CASH EQUIVALENTS - END OF PERIOD	13,377	21,799
Supplemental cash flow information:
Cash paid for interest	12,871	0
Cash paid for income taxes	0	0
Schedule of Non-Cash Financing Activities:
Cancellation of common stock	250	117
Common stock issued for commitment fee	250,000	0
Common stock issued to settle accrued liabilities - related party	127,500	561,148
Common stock issued to settle accounts payable and accrued liabilities	203,126	190,000
Accrued litigation settlement paid with loan payable	100,000	0
Debt discount related to beneficial conversion feature	0	234,912
Conversion of accounts payable and accrued liabilities to convertible notes payable	0	90,000
Accrued liabilities - related party converted to convertible notes payable - related party	0	112,500
Loans payable - related party converted to convertible notes payable - related party	372,000	0
Conversion of accrued liabilities - related party to loans payable - related parties	0	30,000
Common stock issued to settle related party advances	0	20,000
Common stock issued for conversion of convertible notes payable and accrued interest	206,849	590,467
Common stock issued for conversion of convertible notes payable and accrued interest - related party	0	676,555
Convertible notes payable and accrued interest- related party converted to convertible notes payable and accrued interest	$ 0	176,502
Common stock issued for subscription receivable	50,550
Debt discount related to original issue discount	$ 49,525	0
Amortization of deferred offering costs	$ 6,961	$ 0

Description of the Business

Description of the Business	12 Months Ended
	Dec. 31, 2022
Description of the Business
Description of the Business	Note 1. Description of the Business United Health Products, Inc. (the “Company”) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp®, is a neutralized, oxidized, regenerated cellulose derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. The Company in the process of seeking regulatory approval to sell our HemoStyp product line into the U.S. Class III and European Union CE Mark surgical markets.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Significant Accounting Policies	Note 2. Significant Accounting Policies Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these factors, there is substantial doubt about the Company's ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital and other business requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. Basis of Presentation The Company prepares its financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ. Cash and Cash Equivalents The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents. Fair Value Measurements Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1. We value assets and liabilities included in this level using dealer and broker quotations, bid prices, quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2022 and 2021. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. Income Taxes The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities which is commonly known as the asset and liability method. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates its tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are ‘‘more-likely-than-not’’ of being sustained by the applicable tax authority. Tax positions not deemed to meet the “more-likely-than-not” threshold are recorded as an expense in the applicable year. The Company does not have a liability for any unrecognized tax benefits. Management’s evaluation of uncertain tax positions may be subject to review and adjustment at a later date based upon factors including, but not limited to, an on-going analysis of tax laws, regulations and interpretations thereof, with due consideration given to the fact that tax periods are open to examination by tax authorities. As of December 31, 2022 and 2021, the Company has approximately $21.8 and $20.0 million of net operating loss carry-forwards, respectively, available to affect future taxable income and has established a valuation allowance equal to the tax benefit of the net operating loss carry forwards and temporary differences as realization of the asset is not assured. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer depending on the shipping terms. No discounts are offered by the Company as part of payment terms. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business. Trade Accounts Receivable and Concentration Risk The Company records accounts receivable at the invoiced amount and does not charge interest. The Company reviews the accounts receivable by amounts due from customers which are past due to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, the Company makes judgments about the creditworthiness of significant customers based on ongoing credit evaluations. The Company will also maintain a sales allowance to reserve for potential credits issued to customers. The Company will determine the amount of the reserve based on historical credits issued. There was no provision for doubtful accounts recorded at December 31, 2022 and 2021. The Company recorded $0 in bad debt expense for the years ended December 31, 2022 and 2021. For the year ended December 31, 2022, one customer accounted for 100% of the Company’s net revenue. For the year ended December 31, 2021, one customer accounted for 100% of the Company’s net revenue. Inventory Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods. December 31, 2022 December 31, 2021 Raw materials $ - $ - Finished goods 34,730 - $ 34,730 $ - During the years ended December 31, 2022 and 2021, the Company determined that $0 and $69,649, needed to be impaired and written-off, respectively. Patents Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed. Accumulated amortization as of December 31, 2022 and December 31, 2021 was $4,050 and $0, respectively. Amortization expense for the years ended December 31, 2022 and 2021 was $4,050 and $0, respectively. Future Amortization Expense Year Amount 2023 $ 4,050 2024 4,050 2025 4,050 2026 4,050 2027 4,050 Thereafter 16,200 $ 36,450 Deferred Offering Costs Deferred offering costs represent specific incremental costs directly attributable to the offering of securities. The deferred offering costs are recorded as an offset to additional paid-in capital and charged against the proceeds received. Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred. The Company incurred $112,036 and $166,510 in advertising and marketing costs during the years ended December 31, 2022 and 2021, respectively. Shipping and Handling Costs The Company includes shipping and handling cost as part of cost of goods sold. Research and Development The Company charges research and development costs to expense when incurred. The Company incurred $624,564 and $237,458 in research and development expenses during the years ended December 31, 2022 and 2021, respectively. Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation-Stock Compensation Per Share Information Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred a net loss for the years ended December 31, 2022 and 2021 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of December 31, 2022 include 49,165,000 of restricted stock units, 2,338,832 shares for convertible notes payable – related parties and 925,887 shares for convertible notes payable. The total potential common shares as of December 31, 2021 include 28,190,000 of restricted stock units. Impairment of Long-lived Assets The Company applies the provisions of ASC 360, Property, Plant and Equipment, When equipment is sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in the results of operations. During the years ended December 31, 2022 and 2021 the Company determined its property and equipment should be impaired and $0 and $101,350 was written off, respectively. Leases The Company has elected not to recognize right-of-use assets and lease liabilities that arise from short-term leases for any class of assets. New and Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, Under current GAAP, there are five accounting models for convertible debt instruments. ASU 2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2) a convertible debt instrument was issued at a substantial premium. Additionally, for convertible debt instruments with substantial premiums accounted for as paid-in capital, the FASB decided to add disclosures about (1) the fair value amount and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in capital. ASU 2020-06 will be effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this accounting pronouncement on January 1, 2022 and it did not have any impact to its financial statements. The Company considers all new pronouncements and management has determined that there have been no other recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions
Related Party Transactions	Note 3. Related Party Transactions Convertible notes payable - related parties As of December 31, 2022 and 2021, convertible notes payable – related parties totaled $478,331 and $0, respectively. As of December 31, 2020, Brian Thom, the Chief Executive Officer had a total outstanding convertible note payable balance of $555,000 and unamortized debt discount of $199,314. During the year ended December 31, 2021, Mr. Thom converted $45,000 of accrued compensation into a convertible note. The note was convertible at $0.50 per share at the discretion of Mr. Thom, had a maturity date of March 31, 2021 and carried an interest rate of 3%. The note resulted in a beneficial conversion feature of $45,000 which was recorded as a debt discount. During the year ended December 31, 2021, Mr. Thom, converted the total outstanding convertible note balance of $600,000, which was related to $450,000 of loans to the Company and $150,000 of accrued compensation along with accrued interest of $10,135 into 1,220,272 shares of common stock leaving $0 owed to Mr. Thom as of December 31, 2021. The debt discount on the convertible notes was amortized during the year and a total of $244,314 for all of Mr. Thom’s notes was amortized to interest expense – related party, which included the unamortized debt discount of $199,314 as of December 31, 2020 and the debt discount of $45,000 recorded during 2021. As of December 31, 2021, the remaining unamortized debt discount was $0. During the year ended December 31, 2022, Mr. Thom, converted $372,000 of a loan payable balance to a convertible note payable. The unpaid accrued interest on the loan payable was transferred to the convertible note payable. The note has an interest rate of 10%, an original issue discount (“OID”) of 7% and has a maturity date of December 31, 2023. The note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $28,000 of a debt discount related to the OID. As of December 31, 2022, the remaining unamortized debt discount was $16,998 and accrued interest associated with the note was $33,897. As of December 31, 2020, Louis Schiliro, the former Chief Operating Officer, had a total outstanding convertible note payable balance of $170,000 and an unamortized debt discount of $69,564. During the year ended December 31, 2021, Mr. Schiliro converted $45,000 of accrued compensation into a convertible note. The note was convertible at $0.50 per share at the discretion of Mr. Schiliro, had a maturity date of March 31, 2021 and carried an interest rate of 3%. The note resulted in a beneficial conversion feature of $45,000 which was recorded as a debt discount. During the year ended December 31, 2021, $175,000 of the convertible note payable along with $1,502 of accrued interest was assigned to one of the Company’s legal counsel leaving a total outstanding balance of $40,000. The remaining balance of $40,000 along with accrued interest was converted into 80,173 shares of common stock leaving $0 owed to Mr. Schiliro as of December 31, 2021. The debt discount on the convertible notes payable was amortized during the year and a total of $114,654 for all of Mr. Schiliro’s notes was amortized to interest expense – related party during the year ended December 31, 2021, which included the unamortized debt discount of $69,654 as of December 31, 2020 and the debt discount of $45,000 recorded during 2021. As of December 31, 2021, the remaining unamortized debt discount was $0. As of December 31, 2020, Kristofer Heaton, the Principal Financial Officer, has a convertible notes payable balance of $3,750 and an unamortized debt discount of $3,750. During the year ended December 31, 2021, Mr. Heaton, converted $22,500 of accrued compensation into a convertible note. The note was convertible at $0.50 per share at the discretion of Mr. Heaton, had a maturity date of March 31, 2021 and carried an interest rate of 3%. The note resulted in a beneficial conversion feature totaling $22,500 which was recorded as a debt discount. The total outstanding principal balance of $26,250 along with accrued interest was converted into 52,666 shares of common stock leaving $0 owed to Mr. Heaton as of December 31, 2021. The debt discount on the convertible notes payable was amortized during the year and a total of $26,250 for all of Mr. Heaton’s convertible notes payable was amortized to interest expense – related party during the year ended December 31, 2021, which included the unamortized debt discount of $3,750 as of December 31, 2020 and the debt discount of $22,500 recorded during the 2021. As of December 31, 2021, the remaining unamortized debt discount was $0. During the year ended December 31, 2022, Robert Denser, Director of the Company, loaned the Company $93,000 through a convertible note. The note has an interest rate of 10%, an OID of 7% and has a maturity date of December 31, 2023. The note is convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $7,000 of a debt discount related to the OID. As of December 31, 2022, the remaining unamortized debt discount was $4,671 and accrued interest associated with the note was $4,034. Interest expense – related party on the above convertible notes payable was $36,531 (including $13,331 of debt discount amortization related to the OID) and $389,804 (including $385,218 of debt discount amortization) during the year ended December 31, 2022 and 2021, respectively. Accrued interest – related party due to these convertible notes was $37,931 and $0, as of December 31, 2022 and 2021, respectively. Loans payable/Advances - related parties As of December 31, 2022 and 2021, loans payable – related parties totaled $4,000 and $219,000, respectively. During the year ended December 31, 2021, Mr. Thom loaned the Company a total of $175,000 to pay for operating expenses. The loans had an interest rate of 10% and had a maturity date of December 31, 2022. During the year ended December 31, 2022, Mr. Thom loaned the Company $315,000 to pay for operating expenses. The loans had an interest rate of 10% and was due on demand. The Company repaid $118,000 in principal and $6,569 of accrued interest and $372,000 of principal was converted to a convertible note payable and any unpaid accrued interest was transferred to the convertible note payable as mentioned above. The outstanding balance owed to Mr. Thom on the loan payable was $0 and $175,000 as of December 31, 2022 and 2021, respectively. Accrued interest on the loan payable was $0 and $2,125 as of December 31, 2022 and 2021, respectively. During the year ended December 31, 2021, Mr. Schiliro advanced the Company $34,000 to pay for operating expenses and paid $30,000 of expenses on behalf of the Company. During the year ended December 31, 2021, the Company issued 25,000 shares of common stock to settle $20,000 of the outstanding balance leaving a balance of $44,000 as of December 31, 2021. The shares of common stock had a fair market value of $26,750 and the Company recorded a loss on debt settlement of $6,750. During the year ended December 31, 2022, Mr. Schiliro, loaned the Company $64,275 to pay for operating expenses. The loans had an interest rate of 10% and was due on demand. The Company repaid $108,275 in principal and $5,802 of accrued interest leaving a balance of $0 on the loan payable and accrued interest owed to Mr. Schiliro as of December 31, 2022. During the year ended December 31, Mr. Heaton, loaned the Company $4,000 to pay for operating expenses. As of December 31, 2022, $4,000 in principal and $224 in accrued interest is owed to Mr. Heaton. The loan has an interest rate of 10% and is due on demand. Interest expense – related party on the above loans was $25,292 and $2,308 during the years ended December 31, 2022 and 2021, respectively. Accrued interest – related party as of December 31, 2022 and 2021 was $224 and $2,308, respectively. Accrued liabilities – related parties As of December 31, 2020, $74,056 was owed to Nate Knight, who was the Company’s Chief Financial Officer until November 2020, for accrued compensation and reimbursable expenses. During the year ended December 31, 2021, the Company issued 78,500 shares of common stock to settle the total balance owed of $74,056. The shares of common stock had a fair market value of $82,425 and the Company recorded a loss on debt settlement of $8,368. As of December 31, 2021, $899 was owed to Mr. Thom, for reimbursable expenses. During the year ended December 2021, $45,000 of compensation was converted into convertible loans as mentioned above and $135,000 of accrued compensation was settled with the issuance of 270,000 shares of common stock. The stock had a fair market value of $221,400 which resulted in a $86,400 loss on settlement of debt (see Note 6). During the year ended December 31, 2022, the Company had accrued Mr. Thom’s 2022 first quarter compensation of $45,000 and during the second quarter of 2022, the Company issued 150,000 shares of common stock to Mr. Thom to settle the accrued compensation. The common stock had a fair value of $72,000 and the Company recorded $27,000 as a loss on settlement of debt. The Company also paid him $899 for reimbursable expenses leaving a balance of $0 owed for reimbursable expenses. As of December 31, 2020, $59,467 was owed to Mr. Schiliro, for accrued salary and reimbursable expenses, respectively. During the year ended December 31, 2021, $45,000 of accrued compensation was converted into a convertible note as mentioned above, 74,335 shares of common stock were issued to settle the total prior year balance owed of $59,467 and 270,000 shares of common stock were issued to settle $135,000 of accrued compensation. The shares of common stock had a total fair market value of $300,938 and the Company recorded a loss on settlement of debt in the amount of $106,471 (see Note 6). During the year ended December 31, 2022, the Company had accrued Mr. Schiliro’s 2022 first quarter compensation of $45,000 and during the second quarter of 2022, the Company issued 150,000 shares of common stock to Mr. Schiliro for the accrued compensation. The common stock had a fair value of $72,000 and the Company recorded $27,000 as a loss on settlement of debt. As of December 31, 2022, $6,923 was owed to Mr. Schiliro, for reimbursable expenses. As of December 31, 2020, $52,625 was owed to Mr. Heaton, for accrued compensation and services provided. During the year ended December 31, 2021, $22,500 of compensation was converted into a convertible note as described above and 320,250 shares of common shares of stock were issued to settle $105,000 of accrued compensation and $52,625 of prior accruals. The shares of common stock had a total fair market value of $262,605 and the Company recorded a loss on settlement of debt in the amount of $104,980 (see Note 6). During the year ended December 31, 2022, the Company had accrued Mr. Heaton’s 2022 first quarter compensation of $37,500 and during the second quarter of 2022, the Company issued 125,000 shares of common stock to Mr. Heaton for the accrued compensation. The common stock had a fair value of $60,000 and the Company recorded $22,500 as a loss on settlement of debt. As of December 31, 2022, $45,000, $45,000 and $37,500 of accrued compensation was due to Mr. Thom, Mr. Schiliro and Mr. Heaton, respectively. Equity transactions Per the vesting schedules of certain of the Company’s amended RSU Agreements, on January 1, 2021, 6,760,000 shares of common stock were issued to Mr. Douglas Beplate, former Chairman of the Board, 2,000,000 shares of common stock were issued to Mr. Schiliro and 100,000 shares of common stock were issued to Mr. Heaton. On January 6, 2021, the Board of Directors approved the second amendment to the RSU Agreement between the Company and Mr. Beplate in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSU’s by issuing 21,970,000 shares of common stock. Further, as a bonus in recognition of Mr. Beplate’s service to the Company and in recruitment of new executive management, the Company issued to Mr. Beplate an additional 2,000,000 shares of common stock. The Company recorded $26,127,300 of stock-based compensation expense during the year ended December 31, 2021 related to the accelerated vesting of these RSU’s and issuance of common stock. In December 2020, the Company entered into a second restricted stock unit agreement with Mr. Heaton. The second agreement issued an additional 1,000,000 RSU’s, 500,000 of which were granted on the award date and 500,000 of which would be granted on May 15, 2021 provided his professional services agreement was in effect on that date. The 500,000 RSU’s were granted during 2021 per the agreement. The RSU’s, subject to certain conditions, shall vest upon the achievement of certain Company objectives and milestones. During the year ended December 31, 2021, 200,000 of Mr. Heaton’s RSU’s mentioned above vested due to achievement of certain Company objectives. The Company recorded stock-based compensation expense of $220,000 related to the vesting of these RSU’s which was the grant date fair value. During the year ended December 31, 2021, the Company issued 30,000 shares of common stock to Mr. Thom, 30,000 shares of common stock to Mr. Schiliro and 25,000 shares of common stock to Mr. Heaton for services rendered. The 85,000 shares of common stock had a total fair market value of $69,700. During the year ended December 31, 2022, the Board of Directors approved an amendment to Mr. Thom’s RSU Agreement dated November 24, 2020. The amendment increased the number of RSU’s granted from 11,500,000 to 13,225,000. The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. During the year ended December 31, 2022, the Board of Directors approved an RSU Agreement with Robert Denser, Director of the Board. The agreement grants Mr. Denser 1,000,000 RSU’s which are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. During the year ended December 31, 2022, the Company acquired 2,228,115 shares of common stock from its former Chief Executive Officer as described in Note 6. During the year ended December 31, 2022, the Company issued 300,000 shares of common stock each to Mr. Thom and Mr. Schiliro and 250,000 shares of common stock to Mr. Heaton for compensation in lieu of cash. The common stock had a total fair value of $344,250.

Promissory Note Payable

Promissory Note Payable	12 Months Ended
	Dec. 31, 2022
Promissory Note Payable
Promissory Note Payable	Note 4. Promissory Note Payable During the year ended December 31, 2022, the Company reached a settlement agreement related to Patterson’s counterclaim (see Note 8). The Company agreed to pay $120,000 which had previously been accrued as of December 31, 2021. The Company paid $20,000 of the settlement and entered into a $100,000 promissory note with its legal counsel to fund the payment of the remaining balance. The Company paid $90,864 of principal and $500 in interest expense leaving a principal balance of $9,136 and accrued interest of $0 as of December 31, 2022. The note accrues interest at 1% and requires monthly payments of $9,136 until the balance is paid in full. The promissory note is secured by 200,000 shares of restricted common stock which would have demand registration rights and the Company would file a registration statement within 45 days of the request.

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2022
Convertible Notes
Convertible Notes	Note 5. Convertible Notes Convertible notes 2021 During the year ended December 31, 2021, the service providers and medical advisor converted $90,000 of accrued compensation into convertible notes. The notes were convertible at $0.50 per share at the discretion of the note holders, had a maturity date of March 31, 2021 and carried an interest rate of 3%. These notes resulted in a beneficial conversion feature of $90,000 which was recorded as a debt discount. The debt discount was amortized through the maturity dates and a total of $191,080 was amortized to interest expense during the year ended December 31, 2021, which included the unamortized debt discount of $101,080 as of December 31, 2020 and the $90,000 recorded during the year. The remaining unamortized debt discount is $0. The total outstanding principal balance of $295,000 ($205,000 principal balance from 2020 and $90,000 principal balance from 2021) along with accrued interest of $3,569 was converted into 597,139 shares of common stock leaving $0 owed to the service providers and medical advisor as of December 31, 2021. During the year ended December 31, 2021, one of the Company’s legal counsel was assigned $175,000 worth of convertible notes payable and $1,502 of accrued interest after paying outstanding balances owed to Mr. Schiliro (see Note 3). The Company’s legal counsel converted the entire balance of $176,502 into 350,000 shares of common. During the year ended December 31, 2021, the Company issued a total of $115,000 in convertible notes to two unaffiliated individuals to pay for operating expenses. The notes were convertible at $0.85 per share provided that in the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.85 per share, the conversion price shall be reduced to equal such lower issue price per share. The notes had a maturity date of June 30, 2021 and carried an interest rate of 3%. These notes resulted in a beneficial conversion feature of $32,412 which was recorded as a debt discount. The debt discount was amortized through the maturity dates of the notes. A total amount of $32,412 was amortized to interest expense related to these two notes during the year ended December 31, 2021. During the year ended December 31, 2021, the $115,000 principal balance and $397 of accrued interest was converted into 137,996 shares of common stock leaving a balance of $0 owed on the two convertible notes. Convertible notes 2022 During the year ended December 31, 2022, the Company issued a $200,000 convertible promissory note. The note had an interest rate of 10% and a maturity date of November 30, 2022. The note was convertible into common stock of the Company at $0.40 per share. In November 2022, the Company amended the conversion terms of the convertible promissory note from a conversion price of $0.40 per share to $0.25 per share. The $200,000 principal balance and $6,849 of accrued interest were converted into 827,397 shares of common stock leaving a balance owed of $0 on the convertible note. The reduction in the conversion price was considered an inducement for conversion and the Company recorded $82,223 as loss on settlement of debt. During the year ended December 31, 2022, the Company issued a $93,000 convertible note and a $99,975 convertible note and received total proceeds of $192,975. The notes have an interest rate of 10%, an OID of 7% and have a maturity date of December 31, 2023. The notes are convertible into common stock of the Company at $0.35 per share. In the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.35 per share, the conversion price shall be reduced to equal such lower issue price per share. The Company recorded $14,525 of a debt discount related to the OID. As of December 31, 2022, the remaining unamortized debt discount was $11,323. Interest expense on the above convertible notes payable was $15,505 (including $3,202 of debt discount amortization related to the OID) during the year ended December 31, 2022. Accrued interest as of December 31, 2022 was $5,454 and has been recorded in accrued liabilities on the balance sheet.

Issuances of Securities

Issuances of Securities	12 Months Ended
	Dec. 31, 2022
Issuances of Securities
Issuances of Securities	Note 6. Issuances of Securities Share issuances 2021 During the year ended December 31, 2021, the Company had the following common stock transactions: · A total of 32,490,000 shares of common stock were issued to officers, directors and various consultants related to vesting of RSU’s with a total stock-based compensation cost of $24,467,597. · 2,000,000 shares of common stock were issued to Mr. Beplate as a stock bonus with a stock-based compensation cost of $2,180,000. · 125,000 shares of common stock were sold to an affiliated investor in a private placement for total cash proceeds of $100,000. · 370,455 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $326,000. · 61,000 shares of common stock were sold to Triton Funds LP (“Triton”) for cash proceeds of $53,802 (see below for discussion of the purchase agreement). · 100,000 shares of common stock were issued for settlement of a business consulting agreement with a fair value of $111,000. · 40,000 shares of common stock with a fair value of $32,800 were issued to consultants for services provided. · 85,000 shares of common stock with a fair value of $69,700 were issued to officers of the Company for services provided (see Note 3). · 25,000 shares of commons stock with a fair value of $26,750 were issued to settle $20,000 of related party advances which resulted in a loss on settlement of debt of $6,750 (see Note 3). · 1,013,085 shares of common stock were issued to settle accrued liabilities – related party worth $561,548 and recorded at market value of $867,368 which resulted in a loss on settlement of debt of $306,220 (see Note 3). · 380,000 shares of common stock with a fair value of $311,600 were issued to settle accrued compensation worth $190,000 which resulted in $121,600 loss of settlement of debt. · 1,085,135 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest of $590,467 (see Note 4). · 1,353,111 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest – related party of $676,555 (see Note 3). · 300,000 shares of common stock were issued for litigation settlement with a fair value of $312,000. · 117,647 shares of common stock were cancelled reducing common stock by $117 and increasing additional paid-in capital by the same amount. Triton Purchase Agreement On June 25, 2021, the Company entered into a common stock purchase agreement (the “Triton Purchase Agreement”) with Triton Funds LP (“Triton”) to sell Triton up to $6,000,000 of common stock. The Triton Purchase Agreement expired on June 30, 2022. Share issuances 2022 During the year ended December 31, 2022, the Company had the following common stock transactions: · 579,028 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $149,687. · 672,919 shares of common stock were issued to various consultants to settle $203,126 of accrued liabilities resulting in a loss on settlement of debt of $50,875. · 300,000 shares of common stock with a fair value of $129,000 were issued to consultants for services. · 425,000 shares of common stock were issued to settle $127,500 of accrued liabilities – related party (see Note 3) resulting in a loss of settlement of debt of $76,500. · 850,000 shares of common stock with a fair value of $344,250 were issued to officers and a former officer of the Company for services (see Note 3). · 20,000 shares of common stock with a fair value of $10,200 were issued for legal services. · 757,756 shares of common stock with a fair value of $250,000 were issued as commitment shares. · 827,297 shares of common stock were issued due to conversion of a convertible note payable of $200,000 and accrued interest of $6,849 (see Note 5). · 250,000 shares of common stock were sold to White Lion for $50,550 after legal and administrative fees of $600 were deducted. The $50,550 was received in January 2023 and is shown as a subscription receivable in the balance sheet. On September 1, 2022, the Company entered into a common stock purchase agreement (the “CSPA”) with White Lion Capital, LLC (“White Lion”). Pursuant to the CSPA, the Company has the right, but not the obligation, to require White Lion to purchase up to $10,000,000 of the Company’s common stock, subject to certain limitations and conditions set forth in the CSPA. The Company is required to register the resale of the shares issuable to White Lion under the CSPA with the U.S. Securities and Exchange Commission, as a condition to requesting White Lion purchase shares. On September 7, 2022, we filed a registration statement on Form S-3 to register for resale up to 15,000,000 common shares. The Company’s S-3 registration statement was declared effective by the SEC on September 19, 2022. The Company’s right to sell shares to White Lion commenced on the effective date of the resale registration statement and extends for a period of three years. During this term, the Company may exercise its right to sell shares to White Lion, subject to limitations on the amount of shares that are permitted to be sold with each exercise. The purchase price to be paid by White Lion for such shares will equal 93% the lower of: (i) the volume-weighted average price of the Company’s common stock during a period of five consecutive trading days following the Company’s exercise of its right to sell shares, or (ii) the closing price of the common stock on the day the Company exercises its right to sell shares, subject to a minimum price of $0.25 per share. In consideration for White Lion’s commitment to purchase shares under the CSPA when requested, the Company issued 757,576 shares to White Lion with a fair value of $250,000, as disclosed above. The Company will have the right to terminate the CSPA at any time, at no cost or penalty, upon ten trading days prior written notice. Additionally, White Lion will have the right to terminate the CSPA in accordance with its terms for certain breaches of the CSPA by the Company, a Company bankruptcy filing, or the Company’s CEO, Principal Financial Officer or Director of Operations terminating their respective employment with the Company. During the year ended December 31, 2022, the Company sold 395,000 shares of common stock to White Lion and received net proceeds of $72,395 after legal and administrative fees of $26,200 related to the CSPA were deducted, which were included in the total shares issued for cash disclosed above. See Note 12 “Subsequent Events” to our financial statement include in this report for additional information. Share repurchases 2022 During the year ended December 31, 2022, the Company paid $50,000 to repurchase 142,857 shares of common stock and received 2,085,258 shares of common stock from its former Chief Executive Officer in connection with his remaining $808,781 disgorgement settlement obligation with the SEC (Note 10). The aggregate amount of 2,228,115 shares of common stock were cancelled. Share cancellations 2022 During the year ended December 31, 2022, 250,000 shares of common stock were returned to the Company for no consideration, therefore the Company cancelled the shares, reducing common stock by $250 and increasing additional paid-in capital by the same. Restricted stock units During the year ended December 31, 2020 the Board of Directors approved amendments to its March 25, 2019 RSU Agreement for certain management and consultants to the Company. The amendment resulted in 9,960,000 of the RSU’s vesting on January 1, 2021. The fair value of the 9,960,000 RSU’s was $7,071,600. The compensation expense was being amortized on a straight-line basis from the date of the amendment through January 1, 2021 which is the vesting date. Stock-based compensation of $43,121 was recognized as expense during the year ended December 31, 2021. On January 6, 2021, the Board of Directors approved the second amendment to the Restricted Stock Unit Agreement between the Company and Mr. Beplate, former Chief Executive Officer and current Chairman of the Board, in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSU’s by issuing 21,970,000 shares of common stock. Per ASC 718-20-35, the change in vesting conditions resulted in a modification of the stock-based compensation awards. The modification is considered a Type III modification as described in ASC 718-20-55 and resulted in recording $23,947,300 of stock-based compensation expense which was the fair value of the shares on the date of the modification. In April 2021, the Company entered into an RSU agreement with a service provider granting 750,000 RSU’s on the date of the agreement and will grant an additional 750,000 RSU’s, upon the receipt by the Company of an FDA Class III PMA. The 750,000 RSU’s had a grant date fair value of $664,875. The RSUs, subject to certain conditions, shall vest upon the achievement of certain Company objectives and milestones which management is unable to determine when they will be achieved therefore no compensation expense was recognized during the year ended December 31, 2021. During the year ended December 31, 2021, the Company terminated the services of one of its legal counsels who had an RSU agreement in place. Per the RSU agreement, all of the unvested RSU’s owed to the legal counsel vested immediately upon termination of services. This resulted in 325,000 shares of common stock being issued and $230,750 of stock-based compensation being recorded which was the fair value of the shares on the original grant date of the RSU agreement. During the year ended December 31, 2021, the Company recorded the grant of 100,000 RSU’s to one of its legal counsels and 35,000 of the RSU’s vested. The vested RSU’s had a grant date fair value of $26,425 which was recorded as stock-based compensation expense. As discussed in Note 3, Mr. Heaton was granted 500,000 RSU’s in December of 2020 and an additional 500,000 RSU’s in May of 2021. The vesting conditions are contingent upon the achievement of certain Company objectives and milestones. During the year ended December 31, 2021, certain objectives were achieved which resulted in the vesting of 200,000 of RSU’s granted to Mr. Heaton. The 200,000 RSU’s had a grant date fair value of $220,000 which was recorded as stock-based compensation expense. As described above in Note 3, during the year ended December 31, 2022, the Board of Directors approved an RSU Agreement in which Robert Denser, Director was granted 1,000,000 RSU’s which are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. In addition, Mr. Thom’s original RSU Agreement was amended. The amendment increased the amount of RSU’s granted from 11,500,000 to 13,225,000. The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. During the year ended December 31, 2022, the Board of Directors approved RSU Agreements with four physicians as consideration to acquire their rights to the patent application and related intellectual property rights in the “Method of Forming and Using a Hemostatic Hydrocolloid”, U.S. Patent Office Serial No. 62/875,798, filed July 18, 2019, in which a total of 16,000,000 RSU’s were granted. The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. During the year ended December 31, 2022, the Board of Directors approved an amendment to the original terms of an RSU Agreement with a consultant. The amendment increased the amount of RSU’s granted from 750,000 to 3,000,000. The RSU’s are subject to certain conditions and shall vest upon the achievement of certain Company objectives and milestones. Management is unable to determine if and when FDA approval of a PMA Class III will be awarded to the Company or when a change of control will occur, if at all, and as of December 31, 2022, there was a total of $25,313,630 unrecognized compensation cost related to the restricted stock unit awards. Activity related to our restricted stock units during the year ended December 31, 2021 was as follows: Number of Units Weighted Average Grant Date Fair Value Total awards outstanding at December 31, 2020 59,330,000 $ 0.82 Units granted 23,320,000 $ 1.08 Units Exercised/Released (32,490,000 ) $ 0.97 Units Cancelled/Forfeited (21,970,000 ) $ 0.71 Total awards outstanding at December 31, 2021 28,190,000 $ 0.96 Activity related to our restricted stock units during the year ended December 31, 2022 was as follows: Number of Units Weighted Average Grant Date Fair Value Total awards outstanding at December 31, 2021 28,190,000 $ 0.96 Units granted 31,725,000 $ 0.42 Units Exercised/Released - $ - Units Cancelled/Forfeited (12,250,000 ) $ 1.16 Total awards outstanding at December 31, 2022 47,665,000 $ 0.54

Accrued Litigation Settlement

Accrued Litigation Settlement	12 Months Ended
	Dec. 31, 2022
Accrued Litigation Settlement
Accrued Litigation Settlement	Note 7. Accrued Litigation Settlement On June 15, 2022, the Security and Exchange Commission’s (SEC) investigation of the Company, initially reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, was settled through the filing of a consent judgment without the Company admitting or denying the SEC’s allegations. As part of the settlement, the Company is required to pay a civil penalty of $450,000, payable in four installments as follows: · $50,000 upon the entry of the judgment; · $100,000 within 90 days of the entry of the judgment; · $150,000 within 180 days of the entry of the judgment; and · $150,000 within 270 days of the entry of the judgment, plus statutory interest on payments made after 30 days of the entry of the judgment pursuant to U.S.C. Section 1961 The Company made the initial scheduled payment of $50,000 and the second scheduled payment of $100,000 towards the civil penalty and as of December 31, 2022, the accrued litigation balance is $300,000.

Litigation

Litigation	12 Months Ended
	Dec. 31, 2022
Litigation
Litigation	Note 8. Litigation A Complaint was filed with the United States District Court, Southern District of New York by Steven Safran as Plaintiff against the Company and Douglas Beplate, its CEO, as Defendant. This case was transferred to the United States District Court in Las Vegas, Nevada. Mr. Safran sought damages and monies allegedly owed pursuant to an employment agreement of approximately $734,000 and allegedly unpaid loans of $245,824 provided to Defendants. The Company denied the Plaintiff’s allegations. On July 21, 2021, Mr. Safran and the Defendants entered into a Settlement Agreement and General Release whereby the Company agreed to pay $250,000 in cash and issue 300,000 shares of common stock to Mr. Safran. The 300,000 shares have a fair market value of $312,000. As of December 31, 2021, the 300,000 shares of common stock have been issued and $250,000 in cash has been paid. In March 2021, the Company received payment of $304,273 from Maxim Group LLC, representing the full settlement payment in accordance with a Settlement Agreement in a previously disclosed arbitration between the Company and Maxim that was reached in December 2019. Philip Forman, who served as Chairman, a director, Chief Executive Officer and Chief Medical Advisor of the Company at various times between 2011 and October 2015, filed a lawsuit against the Company and our then-Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The plaintiff has claimed, among other things: that the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not enforceable due to lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the plaintiff sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiff’s 2014 Employment Agreement remains valid and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties’ relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company filed a motion to dismiss the plaintiff’s claims which was denied on March 19, 2020. On May 5, 2021, the plaintiff provided a deposition as instructed by the Court, subsequent to which the Company filed a motion for dismissal of this proceeding . In July 2022, United Health Products filed a motion to reopen discovery for the purpose of developing additional issues it wished to raise at trial. At the beginning of August 2022, the court denied United Health Products’ request to reopen discovery. The court instructed counsel for both parties to meet and confer regarding a Joint Trial Order to be filed with the court. The Joint Trial Order generally details the parties’ position on which issues are to be addressed at trial. The parties are currently seeking to reach agreement on what issues should be addressed at trial. Once the issues have been agreed upon, the Joint Trial Order will be filed with the court and the court will set a trial date. Concurrently with the completion of the Joint Trial Order, the parties are engaged in various settlement negotiations. In 2018, an action was commenced in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third-party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading. The third-party plaintiff alleges that the Company and Mr. Beplate refused to have the restrictive legend on the stock certificate removed under Rule 144 and sought compensatory and punitive damages. The Federal court issued an order that the Securities Exchange Commission should review the claim before the District Court renders a final ruling. Discovery appears to be substantially complete and settlement discussions between the third-party plaintiff and the Company have been initiated. On April 22, 2022 the parties entered in a Settlement Agreement wherein the Company would agree to allow the removal of the restrictive legend as permitted under applicable securities laws and distribution of the shares to affiliates of the plaintiffs. Under the Settlement Agreement the Company will make no payments other than to pay expenses related to its own legal counsel. As mentioned in Note 7 above, the Company settled the SEC’s investigation through the filing of a consent judgment on the terms described in the Company’s Form 8-K filed on April 29, 2022, without the Company admitting or denying the SEC’s allegations. Due to uncertainties inherent in litigation, we cannot predict the outcome of the above legal proceedings. The Company is or was also a party to the following legal proceedings: On February 7, 2020, the Company filed the Original Petition for Fraud and Breach of Contract in the Texas District Court for the 215th Judicial District of Harris County against defendants Patterson Companies Inc., Patterson Management, L.P., Patterson Veterinary, Inc. and Patterson Logistics Services, Inc., and Animal Health International, Inc. On March 5, 2020, the defendants removed the case to U.S. District Court for Southern District of Texas. The defendants filed their answer in federal court on March 12, 2020. The original August 25, 2020 pretrial deadlines were extended. On January 18, 2022, the Company’s claims were dismissed, with prejudice, by the court. On February 9, 2022, the Company and Patterson reached an agreement on settlement of Patterson’s counterclaim. The Company agreed to pay $120,000 which was accrued as of December 31, 2021. The $120,000 settlement payment was paid in full in February 2022. In August 2020, United Health Products filed suit against its former auditors, in Utah State Court, asserting claims related to professional negligence and breach of fiduciary duty. The Company and the defendant, through mediation reached an agreement on settlement in which the defendant agreed to pay $392,000 and the entire amount was paid in September 2022 and recorded as other income in the statement of operations (Note 10).

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2022
Income Tax
Income Tax	Note 9. Income Tax The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 740, Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company did not take any uncertain tax positions and had no adjustments to its income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the years ended December 31, 2022 and 2021. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the period presented. The Company had no accruals for interest and penalties at December 31, 2022 or 2021. The Company’s federal income tax returns for the years ended December 31, 2019 through December 31, 2022 remain subject to examination by the Internal Revenue Service as of December 31, 2022. During 2022 and 2021, the Company incurred net losses and, therefore, has no tax liability. The net deferred tax asset generated by the loss carry-forward has been fully reserved. Net deferred tax assets consist of the following components as of December 31, 2022 and 2021 2022 2021 Deferred tax assets: Net operating loss carryover $ 4,570,400 $ 4,203,500 Accrued related party payroll 17,300 (14,000 ) Valuation allowance (4,587,700 ) (4,189,500 ) Net deferred tax asset $ - $ - The income tax provision differs from the amount of income tax determined by applying the U.S federal income tax rate (21%) for the years ended December 31, 2022 and 2021 due to the following: 2022 2021 Book income $ (354,400 ) $ (6,415,300 ) Related party accrued payroll 17,300 (14,000 ) (Gain) Loss on debt settlement 44,000 91,300 Stock for services and compensation 101,500 5,706,400 Interest amortization 3,500 127,800 Inventory write-off - 14,600 Property and equipment write-off - 21,300 Other non-deductible (169,800 ) - Valuation allowance 357,900 467,900 Income tax expense $ - $ - As of December 31, 2022 and 2021, the Company has taxable net loss carryovers of approximately $21.8 and $20.0 million, respectively, that may be offset against future taxable income.

Other Income

Other Income	12 Months Ended
	Dec. 31, 2022
Other Income
Other income	Note 10. Other Income As described in Note 8 above, during the year ended December 31, 2021, the Company received payment of $304,273 from Maxim Group LLC, as full and final settlement of its previously disclosed arbitration between the Company and Maxim that was settled in December 2019. The $304,273 was recorded as other income in the Statement of Operations. During the year ended December 31, 2022, as described in Note 8 above, the Company received $392,000 as a settlement payment from its former auditor. The Company also received $202,200 in cash and 2,085,258 shares of its common stock to satisfy its former Chief Executive Officer’s remaining $808,781 disgorgement obligation under a settlement with the SEC to the SEC (Note 6). The total amount of $1,402,981 was recorded as other income in the Statement of Operations.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	Note 11. Leases On October 31, 2022, the Company signed a 120-day lease for 600 square feet of space in Hammonton, New Jersey to install and test its medical device equipment. The agreement required $2,500 upon signing the agreement and monthly payments of $2,500. As of December 31, 2022, the Company had not made any payments on the lease agreement and had accrued $7,500 related to the lease expense.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2022
Subsequent Event
Subsequent Events	Note 12. Subsequent Events The Company has evaluated events from December 31, 2022, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed, except as follows: On January 25, 2023, the Company and White Lion amended the CSPA to provide that if the Company issues a share price purchase notice at a time that the Company’s common stock is trading below $0.25 per share and White waives the minimum price condition, the share purchase price multiplier for that transaction will be 90% instead of 93%. All other terms, conditions and provisions of the CSPA, remain in full force and effect. The Company issued 3,472,500 shares of common stock for the following: · 3,378,750 shares of common stock were sold to White Lion and received net proceeds of $527,350 after administrative fees related to the CSPA of $600 were deducted. · 937,500 shares of common stock were issued to officers and consultants for $187,500 of accrued compensation.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Going Concern	The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these factors, there is substantial doubt about the Company's ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital and other business requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.
Basis of Presentation	The Company prepares its financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.
Use of Estimates	The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.
Cash and Cash Equivalents	The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.
Fair Value Measurements	Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1. We value assets and liabilities included in this level using dealer and broker quotations, bid prices, quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2022 and 2021. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.
Income Taxes	The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities which is commonly known as the asset and liability method. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates its tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are ‘‘more-likely-than-not’’ of being sustained by the applicable tax authority. Tax positions not deemed to meet the “more-likely-than-not” threshold are recorded as an expense in the applicable year. The Company does not have a liability for any unrecognized tax benefits. Management’s evaluation of uncertain tax positions may be subject to review and adjustment at a later date based upon factors including, but not limited to, an on-going analysis of tax laws, regulations and interpretations thereof, with due consideration given to the fact that tax periods are open to examination by tax authorities. As of December 31, 2022 and 2021, the Company has approximately $21.8 and $20.0 million of net operating loss carry-forwards, respectively, available to affect future taxable income and has established a valuation allowance equal to the tax benefit of the net operating loss carry forwards and temporary differences as realization of the asset is not assured.
Revenue Recognition	The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer depending on the shipping terms. No discounts are offered by the Company as part of payment terms. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.
Trade Accounts Receivable and Concentration Risk	The Company records accounts receivable at the invoiced amount and does not charge interest. The Company reviews the accounts receivable by amounts due from customers which are past due to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, the Company makes judgments about the creditworthiness of significant customers based on ongoing credit evaluations. The Company will also maintain a sales allowance to reserve for potential credits issued to customers. The Company will determine the amount of the reserve based on historical credits issued. There was no provision for doubtful accounts recorded at December 31, 2022 and 2021. The Company recorded $0 in bad debt expense for the years ended December 31, 2022 and 2021. For the year ended December 31, 2022, one customer accounted for 100% of the Company’s net revenue. For the year ended December 31, 2021, one customer accounted for 100% of the Company’s net revenue.
Inventory	Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods. December 31, 2022 December 31, 2021 Raw materials $ - $ - Finished goods 34,730 - $ 34,730 $ - During the years ended December 31, 2022 and 2021, the Company determined that $0 and $69,649, needed to be impaired and written-off, respectively.
Patents	Patents are stated on the balance sheet at cost. Costs, such as filing fees with patent granting agencies and legal fees directly relating to those filings, incurred to file patent applications were capitalized when the Company believed that there was a high likelihood that the patent would be issued and there would be future economic benefit associated with the patent. These costs were amortized from the date of the patent application on a straight-line basis over the estimated useful life of 10 years. All costs associated with any abandoned patent applications are expensed. Accumulated amortization as of December 31, 2022 and December 31, 2021 was $4,050 and $0, respectively. Amortization expense for the years ended December 31, 2022 and 2021 was $4,050 and $0, respectively. Future Amortization Expense Year Amount 2023 $ 4,050 2024 4,050 2025 4,050 2026 4,050 2027 4,050 Thereafter 16,200 $ 36,450
Deferred Offering Costs	Deferred offering costs represent specific incremental costs directly attributable to the offering of securities. The deferred offering costs are recorded as an offset to additional paid-in capital and charged against the proceeds received.
Shipping and Handling Costs	The Company includes shipping and handling cost as part of cost of goods sold.
Research and Development	The Company charges research and development costs to expense when incurred. The Company incurred $624,564 and $237,458 in research and development expenses during the years ended December 31, 2022 and 2021, respectively.
Advertising and Marketing Costs	Advertising and marketing costs are expensed as incurred. The Company incurred $112,036 and $166,510 in advertising and marketing costs during the years ended December 31, 2022 and 2021, respectively.
Stock Based Compensation	The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation-Stock Compensation
Per Share Information	Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred a net loss for the years ended December 31, 2022 and 2021 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of December 31, 2022 include 49,165,000 of restricted stock units, 2,338,832 shares for convertible notes payable – related parties and 925,887 shares for convertible notes payable. The total potential common shares as of December 31, 2021 include 28,190,000 of restricted stock units.
Impairment of Long-lived Assets	The Company applies the provisions of ASC 360, Property, Plant and Equipment, When equipment is sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in the results of operations. During the years ended December 31, 2022 and 2021 the Company determined its property and equipment should be impaired and $0 and $101,350 was written off, respectively.
Leases	The Company has elected not to recognize right-of-use assets and lease liabilities that arise from short-term leases for any class of assets.
New and Recently Adopted Accounting Pronouncements	In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, Under current GAAP, there are five accounting models for convertible debt instruments. ASU 2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2) a convertible debt instrument was issued at a substantial premium. Additionally, for convertible debt instruments with substantial premiums accounted for as paid-in capital, the FASB decided to add disclosures about (1) the fair value amount and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in capital. ASU 2020-06 will be effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this accounting pronouncement on January 1, 2022 and it did not have any impact to its financial statements. The Company considers all new pronouncements and management has determined that there have been no other recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Significant Accounting Policies
Schedule of Inventory	December 31, 2022 December 31, 2021 Raw materials $ - $ - Finished goods 34,730 - $ 34,730 $ -
Schedule of Future Amortization Expense	Year Amount 2023 $ 4,050 2024 4,050 2025 4,050 2026 4,050 2027 4,050 Thereafter 16,200 $ 36,450

Issuances of Securities (Tables

Issuances of Securities (Tables)	12 Months Ended
	Dec. 31, 2022
Issuances of Securities
Schedule of Restricted Stock Units	Number of Units Weighted Average Grant Date Fair Value Total awards outstanding at December 31, 2020 59,330,000 $ 0.82 Units granted 23,320,000 $ 1.08 Units Exercised/Released (32,490,000 ) $ 0.97 Units Cancelled/Forfeited (21,970,000 ) $ 0.71 Total awards outstanding at December 31, 2021 28,190,000 $ 0.96 Number of Units Weighted Average Grant Date Fair Value Total awards outstanding at December 31, 2021 28,190,000 $ 0.96 Units granted 31,725,000 $ 0.42 Units Exercised/Released - $ - Units Cancelled/Forfeited (12,250,000 ) $ 1.16 Total awards outstanding at December 31, 2022 47,665,000 $ 0.54

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax
Schedule of deferred tax assets	2022 2021 Deferred tax assets: Net operating loss carryover $ 4,570,400 $ 4,203,500 Accrued related party payroll 17,300 (14,000 ) Valuation allowance (4,587,700 ) (4,189,500 ) Net deferred tax asset $ - $ -
Schedule of income tax provision	2022 2021 Book income $ (354,400 ) $ (6,415,300 ) Related party accrued payroll 17,300 (14,000 ) (Gain) Loss on debt settlement 44,000 91,300 Stock for services and compensation 101,500 5,706,400 Interest amortization 3,500 127,800 Inventory write-off - 14,600 Property and equipment write-off - 21,300 Other non-deductible (169,800 ) - Valuation allowance 357,900 467,900 Income tax expense $ - $ -

Significant Accounting Polici_4

Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Significant Accounting Policies
Raw materials	$ 0	$ 0
Finished goods	34,730	0
Total Inventory	$ 34,730	$ 0

Significant Accounting Polici_5

Significant Accounting Policies (Details 1)	Dec. 31, 2022 USD ($)
Significant Accounting Policies
2023	$ 4,050
2024	4,050
2025	4,050
2026	4,050
2027	4,050
Thereafter	16,200
Future Amortization Expense	$ 36,450

Significant Accounting Polici_6

Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Bad debt expense	$ 0	$ 0
Amortization expense	4,050	0
Net operating loss carry-forwards	21,800,000	20,000,000
Advertising and Marketing Costs	112,036	166,510
Research and development expenses	624,564	$ 237,458
Description of patent		straight-line basis over the estimated useful life of 10 years
Impaired and written-off	0	$ 69,649
Write-off of property and equipment	$ 0	$ 101,350
Sales Revenue Net [Member] | One Customer [Member]
Concentration of credit risk	100%	100%
Patents [Member]
Accumulated amortization	$ 4,050	$ 0
Convertible Notes Payable - Related Party [Member]
Potential antidilutive shares	2,338,832
Convertible Notes Payable [Member]
Potential antidilutive shares	925,887
Restricted Stock Units [Member]
Potential antidilutive shares	49,165,000	28,190,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)				12 Months Ended
	May 15, 2021	Jan. 06, 2021	Jan. 02, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Interest rate				10%	3%
Pay for operating expenses				$ 2,820,895	$ 29,800,669
Debt discount				16,533	$ 608,710
Convertible notes payable				$ 192,975
Common stock, shares issued				230,871,034	228,667,229
Stock for services and compensation				$ 483,450	$ 26,861,097
Equity Transactions [Member] | Brian Thom [Member]
Common stock, shares issued				300,000	30,000
Mr Thom RSU Amendement [Member]
Number of RSU's granted				from 11,500,000 to 13,225,000
Robert Denser RSU Amendement [Member]
Number of RSU's granted				1,000,000
Robert Denser [Member]
Maturity date of convertible note payable				Dec. 31, 2023
Receive loan through convertible note				$ 93,000
Interest rate				10%
Origina issue discount				7%
Convertible into common stock				$ 0.35
Debt discount				$ 7,000
Unamortized debt discount				4,671
Accrued interest				4,034
Interest expense related party				36,531	$ 389,804
Accrued interest related party				$ 37,931	0
Mr. Heaton [Member]
Stock for services and compensation					$ 220,000
Restricted stock units, vesting					200,000
Mr. Heaton [Member] | Accrued Liabilities Related Parties [Member]
Accrued compensation converted into convertible note					$ 22,500
Common stock, shares issued				125,000		320,250
Common stock fair market value				$ 60,000		$ 262,605
Loss on debt settlement				22,500		105,000
Accrued compensastion for first quarter				37,500
Accrued compensation and services						52,625
Accrued compensastion due				$ 37,500
Brain Thom [Member]
Maturity date of convertible note payable				Dec. 31, 2023
Interest rate					3%
Origina issue discount				7%
Convertible into common stock				$ 0.35
Maturity date					Mar. 31, 2021
Debt discount				$ 28,000	$ 45,000
Unamortized debt discount				16,998	0	199,314
Accrued interest				33,897	10,135
Outstanding convertible note payable						555,000
Accrued compensation converted into convertible note					$ 45,000
Note convertible rate					$ 0.50
Outstanding convertible note balance					$ 600,000
Outstanding convertible note related with loans					450,000
Accrued compensastion					$ 150,000
Converted number of share					1,220,272
Debt discount on the convertible notes					$ 244,314
Loan payable balance to a convertible note payable				$ 372,000
Accrued interest rate				10%
Convertible into common stock issue price before maturity date				$ 0.35
Louis Schiliro [Member]
Convertible note payable					$ 45,000
Interest rate					3%
Maturity date					Mar. 31, 2021
Debt discount					$ 45,000
Unamortized debt discount						69,564
Accrued interest					$ 1,502
Outstanding convertible note payable						170,000
Note convertible rate					$ 0.50
Converted number of share					80,173
Debt discount on the convertible notes					$ 114,654
Convertible notes payable					$ 175,000
Louis Schiliro [Member] | Equity Transactions [Member]
Common stock, shares issued				250,000	30,000
Common stock share issue during			2,000,000
Kristofer Heaton [Member]
Convertible note payable						3,750
Interest rate					3%
Maturity date					Mar. 31, 2021
Debt discount					$ 22,500
Unamortized debt discount						$ 3,750
Accrued compensation converted into convertible note					$ 22,500
Note convertible rate					$ 0.50
Converted number of share					52,666
Debt discount on the convertible notes payable					$ 26,250
Kristofer Heaton [Member] | Equity Transactions [Member]
Common stock, shares issued					25,000
Common stock fair market value				$ 344,250	$ 69,700
Common stock share issue during			100,000		85,000
Stock for services and compensation					$ 220,000
Additional RSU's issued						1,000,000
Additional Restricted stock units granted	500,000					500,000
Restricted stock units, vesting					500,000
Nate Knight [Member] | Accrued Liabilities Related Parties [Member]
Common stock, shares issued					78,500
Common stock fair market value				82,425
Loss on debt settlement				$ 8,368
Accrued compensation and reimbursable expenses						$ 74,056
Balance owed					$ 74,056
Mr. Beplate [Member] | Equity Transactions [Member]
Common stock share issue during		2,000,000	6,760,000
Restricted stock units granted		21,970,000
Stock for services and compensation		$ 26,127,300
Chief Executive Officer [Member]
Common stock share acquire				2,228,115
Mr. Schiliro [Member] | Accrued Liabilities Related Parties [Member]
Accrued compensation converted into convertible note					$ 45,000
Common stock, shares issued				150,000	74,335
Common stock fair market value				$ 72,000		300,938
Loss on debt settlement				27,000		106,471
Reimbursable expenses				6,923
Accrued compensastion for first quarter				45,000
Accrued salary and reimbursable expenses						$ 59,467
common stock issue settlement of accrued compensastion					270,000
Accrued compensastion due				$ 45,000
Mr. Thom [Member] | Accrued Liabilities Related Parties [Member]
Common stock, shares issued				150,000
Common stock fair market value				$ 72,000
Loss on debt settlement				27,000
Reimbursable expenses				899	$ 899
Compensation was converted into convertible loans					45,000
Accrued compensastion for first quarter				45,000
Accrued compensastion due				45,000
Convertible Notes Payable - Related Party [Member]
Convertible note payable				478,331	0
Loans Payable Advances Related Parties [Member]
Loans payable related parties				$ 4,000	219,000
Loans Payable Advances Related Parties [Member] | Mr. Heaton [Member]
Interest rate				10%
Pay for operating expenses				$ 4,000
Accrued interest				224	2,308
Interest expense related party				$ 25,292	2,308
Loans Payable Advances Related Parties [Member] | Mr. Schiliro [Member]
Interest rate				10%
Pay for operating expenses				$ 64,275	34,000
Accrued interest				5,802
Expenses					$ 30,000
Common stock, shares issued					25,000
Outstanding balance					$ 44,000
Common stock fair market value				26,750
Loss on debt settlement				6,750
Loans Payable Advances Related Parties [Member] | Mr. Thom [Member]
Loan payable amount				$ 0	$ 175,000
Interest rate				10%	10%
Pay for operating expenses				$ 315,000	$ 175,000
Maturity date					Dec. 31, 2022
Accrued interest				0	$ 2,125
Loan payable				118,000
Loan amount converted to a convertible note payable				$ 372,000

Promissory Note Payable (Detail

Promissory Note Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accrued	$ 120,000	$ 120,000
Maturity Date	Dec. 31, 2022
Promissory note payable	$ 9,136	0
Interest expense	17,022	$ 226,139
Legal Counsel [Member]
Principal balance	9,136
Monthly payments	$ 9,136
Accrues interest	1%
Promissory note	$ 100,000
Promissory note payable	90,864
Interest expense	500
Accrued interest	$ 0
Restricted stock units, vesting	200,000
Payment for settlement of debt	$ 20,000

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2022	Nov. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Convertible note per share		$ 0.25		$ 0.50
Maturity Date			Nov. 30, 2022
Accrued compensation convert convertible notes				$ 90,000
Outstanding principal balance	$ 295,000		$ 295,000	90,000	$ 205,000
Accrued Interest	5,454		5,454	0
Issuance Of Convertible Promissory Note			200,000
Convertible note payable	99,975		$ 99,975	$ 115,000
Converted common stock				137,996
Interest Rate			10%	3%
Due to related party				$ 0
Convertible Common Stock			$ 0.40
Issuance Of Convertible Note			$ 93,000
Convertible Note Common Stock			$ 0.35
Accrued interest				$ 3,569
Convertible Note Interest Rate			10%	3%
Beneficial conversion feature				$ 90,000
Beneficial conversion feature			$ 0	234,912
Original Issue Discount Rate			7%
Promissory note payable	9,136		$ 9,136	0
Interest expense			17,022	226,139
Debt discount amortization related to OID	$ 3,202		14,525
Debt Discount				191,080
Unamortized Debt Discount			11,323	$ 101,080
Proceeds of convertible note			$ 192,975
Maturity Date Of Convertible Note			December 31, 2023	March 31, 2021
Interest expense other			$ 15,505
Mr. Schiliro [Member]
Converted common stock				350,000
Accrued interest				$ 1,502
Promissory note payable				175,000
Converted common stock amount				176,502
Unaffiliated [Member]
Convertible note per share		$ 0.40
Principal balance		$ 200,000		$ 115,000
Converted common stock		827,397		597,139
Loss on settlement of debt		$ 82,223
Accrued interest		$ 6,849
Beneficial conversion feature				$ 32,412
Interest expense				$ 32,412

Issuances of Securities (Detail

Issuances of Securities (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Issuances of Securities
Number of units total awards outstanding, beginning	28,190,000	59,330,000
Number of units granted	31,725,000	23,320,000
Number of units exercised/released	0	(32,490,000)
Number of units cancelled/forfeited	(12,250,000)	(21,970,000)
Number of units total awards outstanding, ending	47,665,000	28,190,000
Weighted Average Grant Date Fair Value
Weighted average total awards outstanding, beginning	$ 0.96	$ 0.82
Weighted average units granted	0.42	1.08
Weighted average units exercised/released	0	0.97
Weighted average units cancelled/forfeited	1.16	0.71
Weighted average total awards outstanding, ending	$ 0.54	$ 0.96

Issuances of Securities (Deta_2

Issuances of Securities (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended	12 Months Ended
	Jun. 25, 2021	Apr. 30, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Nov. 30, 2022
Common stock shares cancellations				2,228,115
Repurchase common shares				$ 50,000
Common stock shares received				2,085,258
common stock settlement of disgorgement obligation				$ 808,781
Unrecognized compensation cost				$ 25,313,630
Repurchase shares of common stock				142,857
Convertible note per share					$ 0.50	$ 0.25
Loss on settlement of debt				$ (209,598)	$ (434,570)
Subscription receivable				50,550
Proceeds from issuance of cost				175,887	479,802
Related party advances				383,275	245,500
Accrued interest				$ 5,454	0
Common stock, shares issued for service renderred, shares				250,000
Legal and administrative fees				$ 600
Stock based compensation expense				$ 483,450	26,861,097
Restricted stock unit, vested				13,225,000
Common stock, shares issued for service renderred, amount				$ 50,550
Common stock, shares issued for service renderred, amount				$ 483,450	$ 26,861,097
Board of Directors [Member]
Restricted stock units granted				16,000,000
Restricted stock unit, vested				750,000	3,000,000
Mr. Heaton [Member]
Restricted stock units, vesting					200,000
Restricted stock units granted				500,000	500,000
Stock based compensation expense					$ 220,000
Fair value of restricted stock units					$ 200,000
January 1, 2021 [Member]
Restricted stock units, vesting					9,960,000
Stock based compensation expense					$ 43,121
Fair value of restricted stock units					$ 7,071,600
Unvested restricted stock units					9,960,000
Legal Counsels [Member]
Fair value of common stock				$ 10,200
Fair value of vesting					$ 26,425
Common stock, shares issued for service renderred, shares				20,000	325,000
Restricted stock units, vesting					35,000
Restricted stock units granted					100,000
Stock based compensation expense					$ 230,750
Litigation Settlement [Member]
Common stock shares issued during the period					300,000
Fair value of common stock					$ 312,000
Share Issuances [Member]
Common stock shares issued during the period				425,000	1,013,085
Accrued liabilities related party				$ 127,500	$ 561,548
Loss on settlement of debt				$ 76,500	306,220
Proceeds from issuance of cost					$ 867,368
Share Issuances 1 [Member]
Common stock shares issued during the period					380,000
Loss on settlement of debt					$ 121,600
Accrued compensation					190,000
Fair value of common stock					311,600
Consultant Agreement [Member]
Fair value of common stock					$ 111,000
Common stock, shares issued for service renderred, shares					100,000
Share Issuances 2021 and 2022 [Member]
Common stock shares issued during the period				672,919	25,000
Accrued liabilities				$ 203,126
Loss on settlement of debt				$ 50,875	$ 6,750
Proceeds from issuance of cost					26,750
Related party advances					$ 20,000
Consultant [Member]
Common stock, shares issued for service renderred, shares				300,000	40,000
Common stock, shares issued for service renderred, amount				$ 129,000	$ 32,800
Commitment Counsel [Member]
Fair value of common stock				$ 757,756
Common stock, shares issued for service renderred, shares				250,000
Common Stock [Member]
Common stock shares cancellations					117,647
Increasing additional paid-in capital					$ 117
Common stock shares issued during the period				3,472,500
Restricted Stock Units [Member]
Restricted stock units granted		750,000			11,500,000
Fair value of restricted stock units		$ 664,875
Restricted stock units, description		the Company entered into an RSU agreement with a service provider granting 750,000 RSU’s on the date of the agreement and will grant an additional 750,000 RSU’s			The amendment accelerated the vesting and immediately settled his remaining RSU’s by issuing 21,970,000 shares of common stock. Per ASC 718-20-35, the change in vesting conditions resulted in a modification of the stock-based compensation awards. The modification is considered a Type III modification as described in ASC 718-20-55 and resulted in recording $23,947,300 of stock-based compensation expense which was the fair value of the shares on the date of the modification
Non Affiliated Investor [Member] | Private Placement [Member]
Common stock shares issued during the period				579,028	370,455
Proceeds from issuance of cost				$ 149,687	$ 326,000
Affiliated Investor [Member] | Private Placement [Member]
Proceeds from issuance of cost					$ 100,000
Common stock, shares issued for service renderred, shares					125,000
Triton Funds LP [Member]
Proceeds from issuance of cost					$ 53,802
Common stock, shares issued for service renderred, shares					61,000
Common stock purchase agreement description	Triton up to $6,000,000 of common stock. The Triton Purchase Agreement expired on June 30, 2022
Chief Executive Officers [Member]
Common stock, shares issued for service renderred, amount				$ 344,250
Officers And Directors [Member]
RSU granted				1,000,000
Common stock, shares issued for service renderred, shares				850,000	32,490,000
Stock based compensation expense					$ 24,467,597
Mr. Beplate [Member]
Common stock, shares issued for service renderred, shares					2,000,000
Stock based compensation expense					$ 2,180,000
Officers [Member]
Common stock, shares issued for service renderred, shares					85,000
Common stock, shares issued for service renderred, amount					$ 69,700
White Lion Capital [Member]
Common stock shares issued during the period				757,576
Additional paid-in capital				$ 72,395
Convertible note per share				$ 0.25
Fair value of common stock				$ 250,000
Legal and administrative fees				$ 26,200
Common stock, shares Purchase			10,000,000
Common stock shares for legal services				395,000
Convertible Notes Payable [Member]
Common stock shares issued during the period				827,297	1,085,135
Convertible note payable				$ 200,000
Accrued interest				$ 6,849	$ 590,467
Convertible Notes Payable 1 [Member]
Common stock shares issued during the period					1,353,111
Accrued interest					$ 676,555

Accrued Litigation Settlement (

Accrued Litigation Settlement (Details Narrative) - USD ($)	1 Months Ended
	Jun. 15, 2022	Dec. 31, 2022
Civil penalty amount	$ 450,000
Initial schedule payment civil penalty		$ 50,000
Initial schedule payment civil penalty seccond		100,000
Accrued litigation balance		$ 300,000
Installment One [Member]
Civil penalty amount	50,000
Installment Two [Member]
Civil penalty amount	100,000
Installment Three [Member]
Civil penalty amount	150,000
Installment Four [Member]
Civil penalty amount	$ 150,000

Litigation (Details Narrative)

Litigation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jul. 21, 2021	Aug. 31, 2020
Accrued	$ 120,000	$ 120,000
Settelment amount				$ 392,000
Litigation settlement, damages sought	120,000
Litigation settlement, amount payable under agreement	$ 300,000	$ 120,000
Common stock shares issued	230,871,034	228,667,229
Other income	$ 1,402,981	$ 304,273
Lead Dog Capital LP [Member]
Loss contingency damages sought, description	in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third-party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading
Steven Safran [Member] | Employment Agreement [Member]
Litigation settlement, damages sought	$ 734,000
Steven Safran [Member] | Unpaid Loans [Member]
Litigation settlement, damages sought	$ 245,824
Steven Safran [Member] | Settlement Agreement [Member]
Litigation settlement, amount payable under agreement		$ 250,000	$ 250,000
Common stock shares issued		300,000
Litigation settlement, shares issued	300,000
Litigation settlement, shares issuable under agreement			300,000
Litigation settlement, shares issuable under agreement, fair value			$ 312,000
Former Chief Executive Officer and Chief Medical Advisor [Member]
Compensatory damages	$ 2,795,000
Loss contingency damages sought, punitive damages	8,280,000
Maxim Group LLC [Member]
Other income		$ 304,273
Maxim Group LLC [Member] | March 2021 [Member]
Other income	$ 304,273

Income Tax (Details)

Income Tax (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryover	$ 4,570,400	$ 4,203,500
Accrued related party payroll	17,300	(14,000)
Valuation allowance	(4,587,700)	(4,189,500)
Deferred tax asset, net	$ 0	$ 0

Income Tax (Details 1)

Income Tax (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax
Book income	$ (354,400)	$ (6,415,300)
Related party accrued payroll	17,300	(14,000)
Loss on debt settlement	44,000	91,300
Stock based compensation	101,500	5,706,400
Interest amortization	3,500	127,800
Inventory write-off	0	14,600
Property and equipment write-off	0	21,300
Other non-deductible	(169,800)	0
Valuation allowance	357,900	467,900
Income tax expense	$ 0	$ 0

Income Tax (Details Narrative)

Income Tax (Details Narrative) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Income Tax
Net loss carryovers	$ 21.8	$ 20

Other Income (Details Narrative

Other Income (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Payment received	$ 392,000
Cash amount received	$ 202,200
Common stock	2,085,258
Disgorgement obligation	$ 808,781
Other income	$ 1,402,981	$ 304,273
Maxim Group LLC [Member]
Other income		304,273
Maxim Group LLC One [Member]
Other income		$ 304,273

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2022	Dec. 31, 2022
Leases
Description about leases medical device equipment	the Company signed a 120-day lease for 600 square feet of space in Hammonton, New Jersey to install and test its medical device equipment
Monthly rent payments	$ 2,500
Lease expense		$ 7,500

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 25, 2023	Dec. 31, 2022
Description of price condition	common stock is trading below $0.25 per share and White waives the minimum price condition, the share purchase price multiplier for that transaction will be 90% instead of 93%
Administrative fees		$ 600
Common Stock [Member]
Common shares issued		3,472,500
Legal Counsel [Member]
Common shares issued		937,500
Consultant [Member]
Accrued compensation		$ 187,500
Unaffiliated Investors [Member]
Common shares issued		3,378,750
Total proceeds		$ 527,350
Administrative fees		$ 600